Ventyx Biosciences, Inc. is a biotech company pioneering the development of selective inhibitors of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases, with a strong global presence and promising future prospects.

Ventyx Biosciences expands its Scientific Advisory Board, positioning itself as a forward-thinking entity in the biotechnology sector with potential to make significant contributions to healthcare.

Ventyx Biosciences, a biotech company focused on autoimmune disease treatments, has expanded its advisory board and continues to navigate market fluctuations with a market capitalization of $98.2 million.